ALKS250117C36000
- 0.00
- 0.000.00%
Alkermes Newsroom
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes Plc (NASDAQ:ALKS)?
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating, Announces Target Price $40
Alkermes Prepares for New Flexibility Post Credit Termination
Analysts Conflicted on These Healthcare Names: Talkspace (TALK), Centene (CNC) and Alkermes (ALKS)
Insider Sale: EVP R&D of $ALKS (ALKS) Sells 61,151 Shares
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), DocGo (DCGO) and Alkermes (ALKS)
Piper Sandler Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $37
Alkermes Insider Sold Shares Worth $441,550, According to a Recent SEC Filing
Alkermes To Present At Evercore ISI HealthCONx Conference; Webcast At 10:25 AM ET
Alkermes Aims for Growth With Neuroscience Focus
Alkermes to Participate in Upcoming Investor Conferences
Investing in Alkermes (NASDAQ:ALKS) Five Years Ago Would Have Delivered You a 39% Gain
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating
Alkermes Buy Recommendation: Strong Drug Pipeline and Strategic Growth Initiatives Highlighted
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Alkermes To Participate In Jefferies London Healthcare Conference At 8:00 AM ET
Alkermes To Present At Stifel Healthcare Conference; Webcast At 8:35 AM ET
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
US Manufacturing Index Rises To 43, Highest Since 2020